﻿<?xml version='1.0' encoding='UTF-8'?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005"><channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="none"><title>StemCellGateway</title><description>StemCellGateway</description><copyright>Copyright ©2009 StemCellGateway. All Rights Reserved.</copyright><publisher>StemCellGateway</publisher><language>en-us</language><lastBuildDate>2010-09-09 08:15:11 AM</lastBuildDate><atom:updated>2010-09-09 08:15:11 AM</atom:updated><ttl>60</ttl><item><title>Stem Cell Reviews and Reports: Generation of Liver Disease-Specific Induced Pluripotent Stem Cells Along with Efficient Differentiation to Functional Hepatocyte-Like Cells</title><description>Type: Report&lt;br&gt;&lt;p&gt;The availability of disease-specific induced pluripotent stem cells (iPSCs) offers a unique opportunity for studying and modeling the effects of specific gene defects on human liver development in vitro and for testing small molecules or other potential therapies for relevant liver disorders. Here we report, for the first time, the derivation of iPSCs by the retroviral transduction of Yamanaka’s factors in serum and feeder-free culture conditions from liver-specific patients with tyrosinemia, glycogen storage disease, progressive familial hereditary cholestasis, and two siblings with Crigler-Najjar syndrome. Furthermore, they were differentiated into functional hepatocyte-like cells efficiently. These iPSCs possessed properties of human embryonic stem cells (hESCs) and were successfully differentiated into three lineages that resembled hESC morphology, passaging, surface and pluripotency markers, normal karyotype, DNA methylation, and differentiation. The hepatic lineage-directed differentiation showed that the iPSC-derived hepatic cells expressed hepatocyte-specific markers. Their functionality was confirmed by glycogen and lipid storage activity, secretion of albumin, alpha-fetoprotein, and urea, CYP450 metabolic activity, as well as LDL and indocyanin green uptake. Our results provide proof of principal that human liver-disease specific iPSCs present an exciting potential venue toward cell-based therapeutics, drug metabolism, human liver development and disease models for liver failure disorders.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9189-3</link><author>Arefeh Ghodsizadeh; Adeleh Taei; Mehdi Totonchi; Ali Seifinejad; Hamid Gourabi; Behshad Pournasr; Nasser Aghdami; Reza Malekzadeh; Navid Almadani; Ghasem Salekdeh; Hossein Baharvand</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Arefeh Ghodsizadeh; Adeleh Taei; Mehdi Totonchi; Ali Seifinejad; Hamid Gourabi; Behshad Pournasr; Nasser Aghdami; Reza Malekzadeh; Navid Almadani; Ghasem Salekdeh; Hossein Baharvand</atom:name></atom:author><cfi:id>6468</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9189-3</guid><pubDate>2010-09-07</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-07</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-07</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Human Multipotent Mesenchymal Stromal Cells from Distinct Sources Show Different In Vivo Potential to Differentiate into Muscle Cells When Injected in Dystrophic Mice</title><description>Type: Report&lt;br&gt;&lt;p&gt;Limb-girdle muscular dystrophies are a heterogeneous group of disorders characterized by progressive degeneration of skeletal muscle caused by the absence or deficiency of muscle proteins. The murine model of Limb-Girdle Muscular Dystrophy 2B, the &lt;em&gt;SJL&lt;/em&gt; mice, carries a deletion in the dysferlin gene. Functionally, this mouse model shows discrete muscle weakness, starting at the age of 4–6 weeks. The possibility to restore the expression of the defective protein and improve muscular performance by cell therapy is a promising approach for the future treatment of progressive muscular dystrophies (PMD). We and others have recently shown that human adipose multipotent mesenchymal stromal cells (hASCs) can differentiate into skeletal muscle when in contact with dystrophic muscle cells &lt;em&gt;in vitro&lt;/em&gt; and &lt;em&gt;in vivo.&lt;/em&gt; Umbilical cord tissue and adipose tissue are known rich sources of multipotent mesenchymal stromal cells (MSCs), widely used for cell-based therapy studies. The main objective of the present study is to evaluate if MSCs from these two different sources have the same potential to reach and differentiate in muscle cells &lt;em&gt;in vivo&lt;/em&gt; or if this capability is influenced by the niche from where they were obtained. In order to address this question we injected human derived umbilical cord tissue MSCs (hUCT MSCs) into the caudal vein of &lt;em&gt;SJL&lt;/em&gt; mice with the same protocol previously used for hASCs; we evaluated the ability of these cells to engraft into recipient dystrophic muscle after systemic delivery, to express human muscle proteins in the dystrophic host and their effect in functional performance. These results are of great interest for future therapeutic application.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9187-5</link><author>N. Vieira; E. Zucconi; C. Bueno; M. Secco; M. Suzuki; P. Bartolini; M. Vainzof; M. Zatz</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>N. Vieira; E. Zucconi; C. Bueno; M. Secco; M. Suzuki; P. Bartolini; M. Vainzof; M. Zatz</atom:name></atom:author><cfi:id>6467</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9187-5</guid><pubDate>2010-09-04</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-04</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-04</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Popular Culture Representations of Science: Views from the Canadian Stem Cell Research Community</title><description>Type: Original Paper&lt;br&gt;No abstract available.</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9164-z</link><author>Timothy Caulfield; Amy Zarzeczny</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Timothy Caulfield; Amy Zarzeczny</atom:name></atom:author><cfi:id>6463</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9164-z</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: An Inhibitor of Arachidonate 5-Lipoxygenase, Nordy, Induces Differentiation and Inhibits Self-Renewal of Glioma Stem-Like Cells</title><description>Type: Original Paper&lt;br&gt;&lt;p&gt;Recent progress in cancer biology indicates that eradication of cancer stem cells (CSCs) is essential for more effective cancer therapy. Unfortunately, cancer stem cells such as glioma stem-like cells (GSLCs) are often resistant to either radio- or chemotherapy. Therefore, screening and development for novel therapeutic modalities against CSCs has been an important emerging field in cancer research. In this study, we report that a synthetic &lt;em&gt;dl&lt;/em&gt;-nordihydroguaiaretic acid compound (&lt;em&gt;dl&lt;/em&gt;-NDGA or “Nordy”), inhibited self-renewal and induced differentiation of GSLCs in vitro and in vivo. We found that Nordy inhibited an enzyme known to be involved in leukemia stem cell and leukemia progression, Alox-5, and attenuated the growth of GSLCs in vitro. Nordy reduced the GSLC pool through a decrease in the CD133&lt;sup&gt;+&lt;/sup&gt; population and abrogated clonogenicity. Nordy appeared to exert its effect via astrocytic differentiation by up-regulation of GFAP and down-regulation of stemness related genes, rather than by inducing apoptosis of GSLCs. The growth inhibition of xenografted glioma by Nordy was more long-lasting compared with that of the akylating agent BCNU, which exhibited significant relapse on drug discontinuation resulting from an enrichment of GSLCs. Meanwhile, transient exposure to Nordy reduced tumorigenecity of GSLCs and induced differentiation of the xenografts. Taken together, we have identified Alox-5 as a novel target in GSLCs and its inhibition with Nordy exhibits therapeutic implications through inducing GSLC differentiation.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9175-9</link><author>Bin Wang; Shi-cang Yu; Jian-yong Jiang; Gavin Porter; Lin-tao Zhao; Zhe Wang; Hong Tan; You-hong Cui; Cheng Qian; Yi-fang Ping; Xiu-wu Bian</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Bin Wang; Shi-cang Yu; Jian-yong Jiang; Gavin Porter; Lin-tao Zhao; Zhe Wang; Hong Tan; You-hong Cui; Cheng Qian; Yi-fang Ping; Xiu-wu Bian</atom:name></atom:author><cfi:id>6464</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9175-9</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Cord Blood Stem Cells for Hematopoietic Transplantation</title><description>Type: Review Paper&lt;br&gt;&lt;p&gt;Cord blood (CB) is an important alternative source of hematopoietic stem cells (HSCs) for transplantation today. The principal drawbacks of cord blood transplantation are the limited number of hematopoietic stem cells and a long time to engraftment. Several promising approaches for engraftment enhancement are under intensive investigation. Such are transplantation with two cord blood units, co transplantation of cord blood and haploidentical HSCs and different methods for expansion of cord blood hematopoietic stem cells. In addition there are several ways for improving of homing of HSCs such as co- infusion of CB hematopoietic stem cells and mesenchymal stem cells, administration of parathyroid hormone (PTH), intra- bone transplantation and targeting the CXCR4/SDF1 system. These strategies are expected to increase the availability of transplantation to adults, for whom the chance to find a cord blood suitable for a single unit transplant is small. Recent advances in elucidation of the molecular mechanisms responsible for the proliferation and self-renewal of hematopoietic stem cells may bring further improvement of the outcomes of cord blood transplantation. This review summarizes the recent progress in the field of cord blood derived hematopoietic stem cells. It presents the strategies applied and points out directions for the future.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9183-9</link><author>Anfisa Stanevsky; Avichai Shimoni; Ronit Yerushalmi; Arnon Nagler</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Anfisa Stanevsky; Avichai Shimoni; Ronit Yerushalmi; Arnon Nagler</atom:name></atom:author><cfi:id>6465</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9183-9</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Liver Stem/Progenitor Cells in the Canals of Hering: Cellular Origin of Hepatocellular Carcinoma with Bile Duct Tumor Thrombi?</title><description>Type: Original Paper&lt;br&gt;&lt;p&gt;It is generally believed that the invasion of hepatocellular carcinoma (HCC) into the biliary tree ultimately leads to the formation of bile duct tumor thrombi (BDTT). However, recent studies revealed that primary tumor might be small, even undetectable, and there was no histopathologic evidence of direct tumor invasion into bile duct wall in some patients. During the last decade, efforts on stem cell biology may shed light on the pathogenesis of BDTT. Presently, accumulating evidence supports the following notions: (1) the canals of Hering (CoH) are the most likely origin of liver stem/progenitor cells (LSPCs) in adult livers; (2) similar signalling pathways may regulate self-renewal in LSPCs and liver cancer cells, and a substantial proportion of liver tumors may often originate from the transformation of LSPCs; and (3) liver cancer contains rare cells with stem cell-like properties, which could derive from malignant transformation of LSPCs. Herein, we propose that HCC with BDTT, especially with small or undetectable primary lesion and/or no histopathologic evidence for bile duct invasion, might arise from LSPCs residing in the CoH and, possibly, some primary lesions are formed firstly within the intrahepatic biliary tree. When “tumor thrombi” extends mainly along bile duct, there might be “BDTT” alone; when it invades into surrounding parenchyma, there might often be small “primary tumor” with “BDTT”. If this holds true, the putative type may be a particular subset of HCC, and most importantly it would facilitate our understanding of stem-cell origin of HCC.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9188-4</link><author>Ningfu Peng; Lequn Li; Xiang Cai; Shaozao Tan; Ting Wu</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Ningfu Peng; Lequn Li; Xiang Cai; Shaozao Tan; Ting Wu</atom:name></atom:author><cfi:id>6466</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9188-4</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Stem Cell Competition for Niche Occupancy: Emerging Themes and Mechanisms</title><description>Type: Review Paper&lt;br&gt;&lt;p&gt;Tissue-specific adult stem cells are responsible for generating a range of various differentiated cells during their life time; these cells are intimately associated with niche for maintenance and function. Recent studies of germline stem cell niches in &lt;em&gt;Drosophila&lt;/em&gt; gonad suggest that stem cells within a niche constantly compete with each other for niche occupancy. Competition within a niche occurs between same type of stem cells as well as different types. In both cases, cell adhesion molecules are critical in mediating the competition.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9128-3</link><author>Rui Zhao; Rongwen Xi</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Rui Zhao; Rongwen Xi</atom:name></atom:author><cfi:id>6255</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9128-3</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Risks and Mechanisms of Oncological Disease Following Stem Cell Transplantation</title><description>Type: Review Paper&lt;br&gt;&lt;p&gt;Unique biological properties of stem cells make them a precious source of cell material for treatment of a number of pathological conditions. Among issues inhibiting transition of stem cell technologies to the clinics, the risk of oncological complications of stem cell-based therapies is the most critical. A massive amount of clinical and experimental data demonstrates that both hematological (including acute and chronic myeloid leukemia) and non-hematological (including teratoma and non-teratoma tumors) malignancies could arise from donor stem cells of different types. A wide spectrum of mechanisms could underlie the development of oncological disease in recipients, including: i) blast transformation of proliferating donor stem cells under persistent action of certain factors in the recipient, thus causing de novo malignancies; ii) contamination of donor cell material with malignant cells; iii) transmission of particular viral subtypes with donor stem cells, combined with immunosuppression therapy effects; iv) uncontrollable proliferation of residual undifferentiated stem cells of various plasticity; and v) karyotypic instability in stem cells following prolonged culturing/expansion in vitro. Potential preventive strategies are diverse and include i) high-throughput cell sorting-based strategies; ii) introduction of suicide genes into the donor stem cell genome; iii) application of apoptosis-inducing epigenetic factors; and some other options.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9134-5</link><author>Sergey Anisimov; Asuka Morizane; Ana Correia</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Sergey Anisimov; Asuka Morizane; Ana Correia</atom:name></atom:author><cfi:id>6293</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9134-5</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Stem/Precursor Cell-Based CNS Therapy: The Importance of Circumventing Immune Suppression by Transplanting Autologous Cells</title><description>Type: Original Paper&lt;br&gt;&lt;p&gt;Stem/precursor cell (SPC) therapy for neurodegeneration and neurotrauma has enormous therapeutic potential, but despite ongoing research efforts the success of clinical trials remains limited. Therapies that utilize immune suppression in combination with SPC transplantation have thus far failed to consider the beneficial role of the immune system in central nervous system (CNS) recovery. Systemic immune suppression may prevent neural repair, and in some cases exacerbate the underlying disorder. Until about a decade ago, immunosuppression for CNS disorders was viewed as a therapeutic target, based on the perception that all immune activity in the CNS was destructive. However, recent studies show that the infiltration of blood-borne immune cells into the CNS following neurotrauma and during chronic neurodegeneration promote CNS protection and regeneration. In the context of SPC therapies, although immune suppression prevents rejection of non-autologous cell grafts, it also prevents the restorative immune response by eliminating the immune mediated guidance cues that are required for SPCs to migrate to the location they are needed, and preventing SPC-mediated immunomodulation. This article argues in favor of transplanting autologous SPCs, particularly bone marrow derived cells. The therapeutic use of autologous SPCs for neural repair circumvents the need for concomitant immune suppression, exploits the immunomodulatory capacity of these cells, and maintains the immune niche that supports neural repair and is required to guide these cells to their appropriate locations. Overall, such an approach accommodates the requirements for translational therapeutics, and provides a standardized platform for reconciling the inherent controversies in the science.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9141-6</link><author>Iris Kulbatski</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Iris Kulbatski</atom:name></atom:author><cfi:id>6294</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9141-6</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Advances in Reprogramming Somatic Cells to Induced Pluripotent Stem Cells</title><description>Type: Review Paper&lt;br&gt;&lt;p&gt;Traditionally, nuclear reprogramming of cells has been performed by transferring somatic cell nuclei into oocytes, by combining somatic and pluripotent cells together through cell fusion and through genetic integration of factors through somatic cell chromatin. All of these techniques changes gene expression which further leads to a change in cell fate. Here we discuss recent advances in generating induced pluripotent stem cells, different reprogramming methods and clinical applications of iPS cells. Viral vectors have been used to transfer transcription factors (Oct4, Sox2, c-myc, Klf4, and nanog) to induce reprogramming of mouse fibroblasts, neural stem cells, neural progenitor cells, keratinocytes, B lymphocytes and meningeal membrane cells towards pluripotency. Human fibroblasts, neural cells, blood and keratinocytes have also been reprogrammed towards pluripotency. In this review we have discussed the use of viral vectors for reprogramming both animal and human stem cells. Currently, many studies are also involved in finding alternatives to using viral vectors carrying transcription factors for reprogramming cells. These include using plasmid transfection, piggyback transposon system and piggyback transposon system combined with a non viral vector system. Applications of these techniques have been discussed in detail including its advantages and disadvantages. Finally, current clinical applications of induced pluripotent stem cells and its limitations have also been reviewed. Thus, this review is a summary of current research advances in reprogramming cells into induced pluripotent stem cells.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9123-8</link><author>Minal Patel; Shuying Yang</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Minal Patel; Shuying Yang</atom:name></atom:author><cfi:id>6297</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9123-8</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Endoplasmic Reticulum Stress Signals in Defined Human Embryonic Stem Cell Lines and Culture Conditions</title><description>Type: Original Paper&lt;br&gt;&lt;p&gt;Human embryonic stem cells (hESCs) are especially resistant to several cellular stresses, but the existence and induction of Endoplasmic Reticulum (ER) stress by culture conditions are unknown. Using qPCR, here, we investigated the behavior of the principal sensors of ER stress and their relation with the feeder layer, the type of conditioned media used in feeder free systems and the upregulation of several differentiation markers. We observed the preservation of pluripotency, and detected differential expression of differentiation markers in HS181 and SHEF1 hESCs growing on Adipose-derived mesenchymal stem cells (ASCs) and feeder-free system with different conditioned media (HEF-CM and ASC-CM). Taken together, these results demonstrate evidence of ER stress events that cells must resolve to survive and maintenance of markers of pluripotency. The early differentiation status defined could progress into a more differentiated state, and may be influenced by culture conditions.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9135-4</link><author>Miguel Blanco-Gelaz; Beatriz Suarez-Alvarez; Gertrudis Ligero; Laura Sanchez; Jose Vidal-Castiñeira; Eliecer Coto; Harry Moore; Pablo Menendez; Carlos Lopez-Larrea</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Miguel Blanco-Gelaz; Beatriz Suarez-Alvarez; Gertrudis Ligero; Laura Sanchez; Jose Vidal-Castiñeira; Eliecer Coto; Harry Moore; Pablo Menendez; Carlos Lopez-Larrea</atom:name></atom:author><cfi:id>6299</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9135-4</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: The iPS Technique Provides Hope for Parkinson’s Disease Treatment</title><description>Type: Review Paper&lt;br&gt;&lt;p&gt;More recently, reprogramming of somatic cells to an embryonic stem cell-like state presents a milestone in the realm of stem cells, making it possible to derive all cell types from any patients bearing specific genetic mutations. With the development of induced pluripotent stem (iPS) cells, we are now able to use the derivatives of iPS cells to study the mechanisms of disease and to perform drug screening and toxicology testing. In addition, differentiated iPS cells are now close to be used in clinical practice. Here we review the progress of iPS technique and the possible application in the area of Parkinson’s disease treatment.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9145-2</link><author>Liang Xu; Yu-Yan Tan; Jian-Qing Ding; Sheng-Di Chen</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Liang Xu; Yu-Yan Tan; Jian-Qing Ding; Sheng-Di Chen</atom:name></atom:author><cfi:id>6301</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9145-2</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Variation in Hematopoietic Potential of Induced Pluripotent Stem Cell Lines</title><description>Type: Report&lt;br&gt;&lt;p&gt;Induced pluripotent stem (iPS) cells were originally generated from somatic cells by ectopic expression of four transcription factor genes: &lt;em&gt;Oct3/4, Sox2, Klf4&lt;/em&gt; and &lt;em&gt;c-Myc&lt;/em&gt;. Currently, iPS cell lines differ in tissue origin, the combination of factors used to construct them, the method of gene delivery and expression of pluripotency markers. Thus to evaluate iPS cells for haematotherapy, the hematopoietic potential among iPS lines should be compared. Here, we compare differentiation capacity of six iPS lines into mesodermal cells and hematopoietic cells (HCs) through embryoid body (EB) formation. We show that the mouse embryonic fibroblast (MEF)-derived iPS lines 20D17 and 178B5 resemble CCE ES cells in terms of morphology in culture, number and size of EBs and differentiation capacity into mesodermal cells compared to iPS cells derived from adults, although all iPS lines could form EBs. The number of mesodermal cells differentiated from MEF-derived iPS cell lines showed a 3.9–407-fold increase compared to that from iPS lines derived from adults. Furthermore, 178B5 iPS cells generated Ter119&lt;sup&gt;+&lt;/sup&gt; erythroid cells (3.35%) efficiently in culture. We conclude that hematopoietic potential differs among the six lines and that MEF-derived 20D17 and 178B5 iPS cells generate HCs more efficiently than adult–derived iPS cells.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9150-5</link><author>Kasem Kulkeaw; Yuka Horio; Chiyo Mizuochi; Minetaro Ogawa; Daisuke Sugiyama</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Kasem Kulkeaw; Yuka Horio; Chiyo Mizuochi; Minetaro Ogawa; Daisuke Sugiyama</atom:name></atom:author><cfi:id>6394</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9150-5</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Culture Conditions and Signalling Networks Promoting the Establishment of Cell Lines from Parthenogenetic and Biparental Pig Embryos</title><description>Type: Report&lt;br&gt;&lt;p&gt;The generation of porcine embryonic stem cells (pESC) would potentially have great impact in the biomedical field given the long-standing history of the pig as a prime animal model for pre-clinical biomedical applications. These cells would also be beneficial for the agricultural area, allowing efficient genetic engineering of this animal, to improve health and production traits. Despite numerous reports, no conclusive results have been obtained on the isolation and propagation of pESC lines and the establishment of pluripotent cells from the pig has remained an elusive goal. In the present study we performed a systematic analysis of different culture media for their ability to support the establishment of homogenous outgrowths from in vitro-produced embryos. Furthermore, we investigated which molecular networks are responsive to the factors contained in the most efficient media, since the identification of dominant signaling pathways that regulate porcine stem-cell pluripotency is likely to facilitate the generation of genuine pESC. Finally we compared IVF blastocysts versus parthenotes as a possible source for putative pESC in terms of blastocyst rate, resilience to immunosurgery procedures, ability to attach to the feeder, to generate outgrowths and to establish stable cell lines.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9153-2</link><author>Tiziana Brevini; Georgia Pennarossa; Laura Attanasio; Arianna Vanelli; Bianca Gasparrini; Fulvio Gandolfi</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Tiziana Brevini; Georgia Pennarossa; Laura Attanasio; Arianna Vanelli; Bianca Gasparrini; Fulvio Gandolfi</atom:name></atom:author><cfi:id>6395</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9153-2</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Selective Removal of Undifferentiated Embryonic Stem Cells from Differentiation Cultures Through HSV1 Thymidine Kinase and Ganciclovir Treatment</title><description>Type: Report&lt;br&gt;&lt;p&gt;Pluripotent cell lines such as embryonic stem cells are an attractive source for a potential cell replacement therapy. However, transplantation of differentiated cells harbors the risk of teratoma formation, presenting a serious health risk. To overcome this obstacle, a negative selection system was established that permits selective removal of undifferentiated cells during in vitro differentiation. Use of the HSV1 thymidine kinase and eGFP under the control of the Oct4 promoter allowed the destruction of undifferentiated ES cells by ganciclovir treatment; differentiated cells were unharmed. Clonal ES cells remained pluripotent and showed positive staining for a wide range of embryonic markers. Thus, treatment with ganciclovir during in vitro differentiation effectively removed the population of undifferentiated cells and provided a pure population of completely differentiated cells. This approach may pave the way for a safe application of ES cells in regenerative medicine in the future.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9148-z</link><author>Ortwin Naujok; Joanna Kaldrack; Terbish Taivankhuu; Anne Jörns; Sigurd Lenzen</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Ortwin Naujok; Joanna Kaldrack; Terbish Taivankhuu; Anne Jörns; Sigurd Lenzen</atom:name></atom:author><cfi:id>6396</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9148-z</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Regulation of Human Stem Cell Research in South Korea</title><description>Type: Brief Communication&lt;br&gt;&lt;p&gt;Human stem cell research has been performed for many years in South Korea. It has been supported by the South Korean government, like other biomedical research. Like many other countries, human embryonic stem cell research, human adult stem cell research and iPS cell research have been performed in South Korea. The Bioethics and Safety Act is the main law which regulates human stem cell research. It took effect on 1 January 2005. However, this Act does not include all the fields of biomedical research and some provisions were not clear. After Hwang’s scandal, there have been heated debates about the revision of the Bioethics and Safety Act. It was revised several times and a new revised version is under consideration now.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9156-z</link><author>Kyu Jung</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Kyu Jung</atom:name></atom:author><cfi:id>6404</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9156-z</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Generation of Human Embryonic Stem Cell Reporter Lines Expressing GFP Specifically in Neural Progenitors</title><description>Type: Report&lt;br&gt;&lt;p&gt;Generation of lineage-specific human embryonic stem cell (hESC) reporter lines will facilitate the real time monitoring of differentiation in live cells and the identification of factors governing these processes. It will also enable researchers to purify specific cell populations from heterogeneous differentiated hESC progeny. Here we report the generation of clonally derived nestin-EGFP reporter hESC lines that express GFP under the control of the neuroepithelial specific nestin 2nd intron enhancer. We show that the nestin-EGFP hESC reporter lines retain the features of undifferentiated hESCs, are able to self-renew in hESC culture conditions and to differentiate into cells of all three germ layers. The nestin-EGFP reporter exhibited high expression in neural progenitor cells upon differentiation, although it is detectable at a low level in the undifferentiated state. Furthermore, the expression of the transgene is exclusively confined to the neural progenitors after differentiation. The specific expression of the transgene is determined by collaborative binding motifs of POU and SOX transcription factors in the nestin enhancer. Deletion of either of the binding elements resulted in a significant reduction of enhancer/promoter activity. Taken together, the nestin-EGFP reporter hESC lines are invaluable not only for the study of the neural differentiation process from hESCs but also for the enrichment of neural progenitor cells from other cell lineages.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9159-9</link><author>Parinya Noisa; Alai Urrutikoetxea-Uriguen; Meng Li; Wei Cui</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Parinya Noisa; Alai Urrutikoetxea-Uriguen; Meng Li; Wei Cui</atom:name></atom:author><cfi:id>6405</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9159-9</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Human Embryonic Stem Cells (hESCs) Cultured Under Distinctive Feeder-Free Culture Conditions Display Global Gene Expression Patterns Similar to hESCs from Feeder-Dependent Culture Conditions</title><description>Type: Report&lt;br&gt;&lt;p&gt;Human embryonic stem cell (hESC)–based assay systems and genetically modified hESCs are very useful tools for screening drugs that regulate stemness and differentiation and for studying the molecular mechanisms involved in hESC fate determination. For these types of studies, feeder cell–dependent cultures of hESCs are often problematic because the physiology of the feeder cells is perturbed by the drug treatments or genetic modifications, which potentially obscures research outcomes. In this study, we evaluated three commonly used feeder-free culture conditions to determine whether they supported the undifferentiated growth of hESCs and to determine whether the hESCs grown in these conditions displayed gene expression patterns that were similar to the expression patterns of feeder cell-dependent hESCs. Our results demonstrate that hESCs grown in the three feeder-free conditions expressed undifferentiation marker genes as strongly as hESCs that were grown in the feeder-dependent cultures. Furthermore, genome-wide gene expression profiles indicated that the gene expression patterns of hESCs that were grown under feeder-free or feeder-dependent culture conditions were highly similar. These results indicate that the feeder-free culture conditions support the undifferentiated growth of hESCs as effectively as the feeder-dependent culture conditions. Therefore, feeder-free culture conditions are potentially suitable for drug screening and for the genetic manipulation of hESCs in basic research.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9158-x</link><author>Tae-Min Yoon; Bomi Chang; Hyeung-Taek Kim; Joo-Hyun Jee; Dong-Wook Kim; Dong-Youn Hwang</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Tae-Min Yoon; Bomi Chang; Hyeung-Taek Kim; Joo-Hyun Jee; Dong-Wook Kim; Dong-Youn Hwang</atom:name></atom:author><cfi:id>6407</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9158-x</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Transplantation of Mammalian Embryonic Stem Cells and Their Derivatives to Avian Embryos</title><description>Type: Review Paper&lt;br&gt;&lt;p&gt;Xenografting of normal and transformed mammalian tissues and cells to chick embryos has been performed for almost 100 years. Embryonic stem cells, derived more than 25 years ago from murine, and more than 10 years ago from human blastocysts, have transformed many fields of biological research. There is a growing body of studies combining these two widely-used experimental systems. This review surveys those reports in which murine or human embryonic stem cells, or differentiated derivatives of these pluripotent stem cells, were transplanted to embryonated chick eggs. Many of these studies have utilized the unique characteristics of both experimental models to obtain answers to developmental questions that are difficult or impossible to approach with xenografting to adult rodents or tissue culture-only techniques.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9161-2</link><author>Ronald Goldstein</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Ronald Goldstein</atom:name></atom:author><cfi:id>6410</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9161-2</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Viable Fertile Mice Generated from Fully Pluripotent iPS Cells Derived from Adult Somatic Cells</title><description>Type: Report&lt;br&gt;&lt;p&gt;Previous studies demonstrated that induced pluripotent stem (iPS) cells could produce viable mice through tetraploid complementation, which was thought to be the most stringent test for pluripotency. However, these highly pluripotent iPS cells were previously reported to be generated from fibroblasts of embryonic origin. Achieving fully pluripotent iPS cells from multiple cell types, especially easily accessible adult tissues, will lead to a much greater clinical impact. We successfully generated high-pluripotency iPS cells from adult tail tip fibroblasts (TTF) that resulted in viable, full-term, fertile TTF-iPS animals with no obvious teratoma formation or other developmental abnormalities. Comparison of iPS cells from embryonic origin (MEF), progenitor cells (neural stem cells) or differentiated somatic cells (TTF) reveals that fully pluripotent developmental potential can be reached by each cell type, although with different induction efficiencies. This work provides the means for studying the mechanisms and regulation of direct reprogramming, and has encouraging implications for future clinical applications and therapeutic interventions.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9160-3</link><author>Xiao-yang Zhao; Wei Li; Zhuo Lv; Lei Liu; Man Tong; Tang Hai; Jie Hao; Xiang Wang; Liu Wang; Fanyi Zeng; Qi Zhou</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Xiao-yang Zhao; Wei Li; Zhuo Lv; Lei Liu; Man Tong; Tang Hai; Jie Hao; Xiang Wang; Liu Wang; Fanyi Zeng; Qi Zhou</atom:name></atom:author><cfi:id>6411</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9160-3</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: G-protein Coupled Receptors in Stem Cell Self-Renewal and Differentiation</title><description>Type: Review Paper&lt;br&gt;&lt;p&gt;Stem cells have great potential for understanding early development, treating human disease, tissue trauma and early phase drug discovery. The factors that control the regulation of stem cell survival, proliferation, migration and differentiation are still emerging. Some evidence now exists demonstrating the potent effects of various G-protein coupled receptor (GPCR) ligands on the biology of stem cells. This review aims to give an overview of the current knowledge of the regulation of embryonic and somatic stem cell maintenance and differentiation by GPCR ligands.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9167-9</link><author>Nao Kobayashi; Susan Hawes; Jeremy Crook; Alice Pébay</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Nao Kobayashi; Susan Hawes; Jeremy Crook; Alice Pébay</atom:name></atom:author><cfi:id>6417</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9167-9</guid><pubDate>2010-09-01</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-09-01</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: The Regenerative Potential of the Kidney: What Can We Learn from Developmental Biology?</title><description>Type: Original Paper&lt;br&gt;&lt;p&gt;Cell turnover in the healthy adult kidney is very slow but the kidney has a strong capacity for regeneration after acute injury. Although many molecular aspects of this process have been clarified, the source of the newly-formed renal epithelial cells is still being debated. Several studies have shown, moreover, that the repair of injured renal epithelium starts from mature tubular cells, which enter into an activated proliferative state characterized by the reappearance of mesenchymal markers detectable during nephrogenesis, thus pointing to a marked plasticity of renal epithelial cells. The regenerative potential of mature epithelial cells might stem from their almost unique morphogenetic process. Unlike other tubular organs, all epithelial and mesenchymal cells in the kidney derive from the same germ layer, the mesoderm. In a fascinating view of vertebrate embryogenesis, the mesoderm might be seen as a cell layer capable of oscillating between epithelial and mesenchymal states, thus acquiring a remarkable plasticity that lends it an extended potential for innovation and a better control of three-dimensional body organization. The renal papilla contains a population of cells with the characteristic of adult stem cells. Mesenchymal stromal stem cells (MSC) have been found to reside in the connective tissue of most organs, including the kidney. Recent studies indicate that the MSC compartment extends throughout the body postnatally as a result of its perivascular location. Developmental biology suggests that this might be particularly true of the kidney and that the papilla might represent the perivascular renal stem cell niche. The perivascular niche hypothesis fits well with the evolving concept of the stem cell niche as an entity of action. It is its dynamic capability that makes the niche concept so important and essential to the feasibility of regenerative medicine.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9186-6</link><author>Franca Anglani; Federica Mezzabotta; Monica Ceol; Rosalba Cristofaro; Dorella Prete; Angela D’Angelo</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Franca Anglani; Federica Mezzabotta; Monica Ceol; Rosalba Cristofaro; Dorella Prete; Angela D’Angelo</atom:name></atom:author><cfi:id>6461</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9186-6</guid><pubDate>2010-08-17</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-08-17</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-08-17</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: ROCK Inhibitor Y-27632 Increases Thaw-Survival Rates and Preserves Stemness and Differentiation Potential of Human Wharton’s Jelly Stem Cells After Cryopreservation</title><description>Type: Original Paper&lt;br&gt;&lt;p&gt;The ROCK inhibitor Y-27632 inhibits apoptosis and increases proliferation of frozen-thawed cells. We examined the role of Y-27632 on human umbilical cord Wharton’s jelly stem cells (hWJSCs) for (1) thaw-survival (2) proliferation and (3) preservation of stemness and differentiation potential after cryopreservation. hWJSCs were allotted to 4 groups [Gp I: Untreated hWJSC controls; Gp II: Pretreatment with Y-27632 (10 μM) for 24 h before freezing; Gp III: Y-27632 (10 μM) in freezing medium and Gp IV: Pretreatment with Y-27632 (10 μM) for 24 h and inclusion in freezing medium]. All groups were frozen using a rapid freezing method and stored at -196°C in liquid nitrogen for 90 days before evaluation for apoptosis, cell proliferation, stemness and differentiation. After thawing, Groups II, III and IV showed improved cell attachment, increased thaw-survival (live/dead cell counts) and increased cell proliferation (Trypan blue and MTT assay) compared to controls. CD marker stemness profiles, morphology and normal karyotypes were maintained in the treatment groups after thawing and there was no obvious evidence of apoptosis (Annexin V-FITC and TUNEL assays). After thawing, qRT-PCR demonstrated up-regulation of the anti-apoptotic BCL2 gene and down-regulation of the pro-apoptotic BAX gene and cell cycle regulators (P53 and P21) in the treatment groups. Treated frozen-thawed hWJSCs from all groups differentiated into a neuronal phenotype (neuronal morphology and expression of GFAP, β-3 tubulin and SOX2). Increased thaw-survival and retention of stemness and differentiation potential in hWJSCs following cryopreservation is useful for their storage in cord blood banks for future regenerative medicine purposes.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9184-8</link><author>Kalamegam Gauthaman; Chui-Yee Fong; Arjunan Subramanian; Arijit Biswas; Ariff Bongso</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Kalamegam Gauthaman; Chui-Yee Fong; Arjunan Subramanian; Arijit Biswas; Ariff Bongso</atom:name></atom:author><cfi:id>6459</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9184-8</guid><pubDate>2010-08-14</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-08-14</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-08-14</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Stem Cell Reviews and Reports: Human Embryonic Stem Cell-extracts Inhibit the Differentiation and Function of Monocyte-derived Dendritic Cells</title><description>Type: Report&lt;br&gt;&lt;p&gt;Embryonic stem cells (ESC) possess inherent properties of immune privilege with the capacity to evade allogeneic immune responses. Moreover, ESCs have been shown to prevent immune activation in response to third party antigen presenting cells in vitro and have the capacity to promote allograft survival in vivo. However, clinical use of human ESCs to treat immunological disorders may risk teratoma or ectopic tissue formation. Here, we show that cellular extracts from both human and mouse ESCs retain the immune modulatory properties of intact cells. ESC-extracts that contained 12–24 μg of total protein effectively prevented T cell proliferation in allogeneic mixed lymphocyte reactions (MLR), whereas control fibroblast extracts did not affect proliferation. Cellular mechanisms underlying hESC extract-mediated immune modulation involve the maturation of monocyte derived dendritic cells (mDC). hESC extract-treated mDCs had reduced surface expression of co-stimulatory and maturation markers CD80, HLA-DR and CD83 and secreted lower levels of IL12p40. Accordingly, hESC extract-treated DCs were found to be poor stimulators of purified allogeneic T cells compared to those DCs treated with vehicle or fibroblast extracts. Our results demonstrate that ESC extracts retain the immune modulatory properties of ESCs and for the first time demonstrates that ESC derived factors can inhibit human mDC maturation and function.&lt;/p&gt;</description><link>http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9185-7</link><author>Kanishka Mohib; David Allan; Lisheng Wang</author><atom:author xmlns:atom="http://www.w3.org/2005/Atom"><atom:name>Kanishka Mohib; David Allan; Lisheng Wang</atom:name></atom:author><cfi:id>6460</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/ArticlePage.aspx?DOI=10.1007/s12015-010-9185-7</guid><pubDate>2010-08-14</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-08-14</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-08-14</atom:updated><category>Stem Cell Reviews and Reports</category></item><item><title>Alert: 1st Stem Cell Symposium with International Participation</title><description>Type: Alert&lt;br&gt;</description><link>http://stemcellgateway.net/Alerts.aspx?itemid=6452</link><cfi:id>6452</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/Alerts.aspx?itemid=6452</guid><pubDate>2010-08-03</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-08-03</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-08-03</atom:updated><category> Alert</category></item><item><title>Alert: Hematopoietic Stem Cell Biology by Kondo, Motonari</title><description>Type: Alert&lt;br&gt;Hematopoietic Stem Cell Biology concisely describes our current understanding of normal hemato/lymphopoiesis as well as abnormal hematopoiesis, which may lead to leukemia. 
</description><link>http://stemcellgateway.net/Alerts.aspx?itemid=6402</link><cfi:id>6402</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/Alerts.aspx?itemid=6402</guid><pubDate>2010-05-14</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2010-05-14</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2010-05-14</atom:updated><category> Alert</category></item><item><title>Alert: NEW!
Announcing increased 2009 Impact Factor of 5.083!</title><description>Type: Alert&lt;br&gt;</description><link>http://stemcellgateway.net/Alerts.aspx?itemid=6090</link><cfi:id>6090</cfi:id><guid isPermaLink="true">http://stemcellgateway.net/Alerts.aspx?itemid=6090</guid><pubDate>2009-07-20</pubDate><atom:published xmlns:atom="http://www.w3.org/2005/Atom">2009-07-20</atom:published><atom:updated xmlns:atom="http://www.w3.org/2005/Atom">2009-07-20</atom:updated><category> Alert</category></item></channel></rss>